evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

43 questions · 45 findings · 7 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 6.7%GRADE not reported 3 · 6.7%Very low 9 · 20%Low 7 · 15.6%Moderate 17 · 37.8%High 6 · 13.3%

GnRH agonist plus chemotherapy vs chemotherapy alone

Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).

1 finding from 1 review

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).

2 findings from 1 review

Intervention not reported

Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 5‐ to 6‐year · people with glioma surviving at least two years

It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).

1 finding from 1 review

Intervention not reported

Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 12 year · people with glioma surviving at least two years

It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).

1 finding from 1 review

Intervention not reported

Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 2 year · people with glioma surviving at least two years

It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).

1 finding from 1 review

Intervention not reported

Death from all causes · patients with early stage cervical cancer

The intervention probably leads to lower death from all causes (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression · patients with early stage cervical cancer

The intervention probably leads to lower disease progression (moderate certainty).

1 finding from 1 review

Intervention not reported

Grade 4 toxicity3 · patients with early stage cervical cancer

The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression · patients with early stage cervical cancer

The intervention showed no clear difference in disease progression (low certainty).

1 finding from 1 review

Intervention not reported

5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention probably leads to lower 5‐ year OS (moderate certainty).

1 finding from 1 review

Intervention not reported

5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention probably leads to lower 5‐year PFS (moderate certainty).

1 finding from 1 review